There is a substantial need for hematology/oncology clinicians to review the latest data on CD19-targeted therapies for R/R DLBCL. This program highlights the science and mechanisms of actions, results from landmark clinical trials, and management of side effects of the available options. Expert insights can aid clinical decision-making when clinical data are limited or emerging. Notably, the place of the non-cellular CD19-targeted therapies can present a challenge to clinicians, especially for those patients who are being considered for CD19-CAR T-cell therapy.